Cash Flow Statement

Amortization of Deferred Charges Amortization of Goodwill Amortizatization of Intangibles Asset Writedowns and Impairment Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Cash from Restructuring Change in Account Payables Change in Accured Expenses Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Receivables Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation and Depletion Dividends Paid - Common Exchange Rate Effect Free Cash Flow Gains from Investment Securities Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Income Non-cash Items Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Altimmune (ALT) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Altimmune (ALT) over the last 10 years, with Q3 2025 value amounting to $113000.0.

Altimmune's Amortization of Deferred Charges changed N/A to $113000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $173587.0, marking a year-over-year change of. This contributed to the annual value of $180611.0 for FY2018, which is 8418.42% up from last year.
As of Q3 2025, Altimmune's Amortization of Deferred Charges stood at $113000.0.
Altimmune's Amortization of Deferred Charges' 5-year high stood at $113000.0 during Q3 2025, with a 5-year trough of $113000.0 in Q3 2025.